Art. -Nr.: HY-145272

ELOVL1-IN-3

Name: ELOVL1-IN-3
Brand: MedChemExpress
SKU: HY-145272
Price: 165.00 USD
Availability: InStock
Rating: 5 (2 reviews)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

ELOVL1-IN-3 (Compound 22) is a potent and orally active inhibitor of elongation of very long chain fatty acid 1 (ELOVL1) enzyme. ELOVL1-IN-3 serves as a useful tool for researching adrenoleukodystrophy (ALD)^[1].

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.93%
CAS. Nr.: 2761063-99-2
Formel: C₂₁H₂₃N₅O₂
Molecular Weight:377.44

Speicherung:

Pure form -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

ELOVL1-IN-3 Chemical Structure

CAS. Nr.: 2761063-99-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

ELOVL1 [1]

In Vitro

ELOVL1-IN-3 (100 nM, 48 hours) selectively inhibits ELOVL1-mediated C26:0 LPC synthesis in HEK293 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. .

In Vivo

ELOVL1-IN-3 (1-32 mg/kg, p.o., once daily, for 3 months) significantly reduced blood C26:0 lysophosphatidylcholine (LPC) levels in ABCD1 knockout C57BL/6 mice^[1].
ELOVL1-IN-3 (10 or 50 mg/kg, p.o., once daily, for 28 days) significantly reduced blood C26:0 lysophosphatidylcholine (LPC) levels in Sprague-Dawley rats^[1].
ELOVL1-IN-3 (6.5 or 50 mg/kg, p.o., once daily, for 14 days) significantly reduced blood C26:0 lysophosphatidylcholine (LPC) levels in cynomolgus monkeys^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

ATP binding cassette transporter D1 (ABCD1) knockout mouse model (Adrenoleukodystrophy (ALD) disease)^[1]
Dosage:

1, 4, 8, 16, or 32 mg/kg
Administration:

Oral gavage (p.o.), once daily for 3 months
Result:

Significantly reduced blood C26:0 LPC levels (8 mg/kg or higher brought levels near wild-type).

Animal Model:

Sprague-Dawley rats
Dosage:

10 or 50 mg/kg
Administration:

Oral gavage (p.o.), once daily for 28 days
Result:

Reduced blood C26:0 LPC levels by 78% and 79%, respectively.

Animal Model:

Cynomolgus monkey
Dosage:

6.5 or 50 mg/kg
Administration:

Oral gavage (p.o.), once daily for 14 days
Result:

Reduced blood C26:0 LPC levels by 47% and 65%, respectively.

Chemical Information

CAS. Nr. 2761063-99-2
Appearance Oil
Molecular Weight 377.44
Formel C₂₁H₂₃N₅O₂
Color Colorless to light yellow
SMILES

[C@@H]1(C2=CC=CC=C2)OCCN(C3=CC(O[C@@H]4C[C@H](N5C=CC=N5)C4)=NC=N3)C1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Pure form	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (2)

All

Sort by:

Journal Impact Factor

Nat Commun

Transcription factor 19 modulates fatty acid elongation and unfolded protein response to attenuate palmitic acid-induced hepatic dysfunction. [Abstract]

2026 Apr 22;17(1):5596. PMID: 42020413
bioRxiv

2025 May 16.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (264.94 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6494 mL

13.2471 mL

26.4943 mL

5 mM

0.5299 mL

2.6494 mL

5.2989 mL

10 mM

0.2649 mL

1.3247 mL

2.6494 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.62 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Boyd MJ, et al. Discovery of Novel, Orally Bioavailable Pyrimidine Ether-Based Inhibitors of ELOVL1. J Med Chem. 2021;64(24):17777-17794. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6494 mL	13.2471 mL	26.4943 mL	66.2357 mL
	5 mM	0.5299 mL	2.6494 mL	5.2989 mL	13.2471 mL
	10 mM	0.2649 mL	1.3247 mL	2.6494 mL	6.6236 mL
	15 mM	0.1766 mL	0.8831 mL	1.7663 mL	4.4157 mL
	20 mM	0.1325 mL	0.6624 mL	1.3247 mL	3.3118 mL
	25 mM	0.1060 mL	0.5299 mL	1.0598 mL	2.6494 mL
	30 mM	0.0883 mL	0.4416 mL	0.8831 mL	2.2079 mL
	40 mM	0.0662 mL	0.3312 mL	0.6624 mL	1.6559 mL
	50 mM	0.0530 mL	0.2649 mL	0.5299 mL	1.3247 mL
	60 mM	0.0442 mL	0.2208 mL	0.4416 mL	1.1039 mL
	80 mM	0.0331 mL	0.1656 mL	0.3312 mL	0.8279 mL
	100 mM	0.0265 mL	0.1325 mL	0.2649 mL	0.6624 mL

Bioz

Keywords

ELOVL1-IN-3

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

ELOVL1-IN-3

Publications Citing Use of MedChemExpress (MCE) ELOVL1-IN-3